Biocartis Group NV reconfirmed earnings guidance of 2022. For the period, the company expects to achieve full year product revenue of EUR 50 million - EUR 55 million, representing growth of 24% - 36% over full year 2021 revenue of EUR 40.5 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.29 EUR | +1.05% | -.--% | -.--% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-.--% | 29.34M | |
+73.37% | 12.39B | |
-17.09% | 8.08B | |
+16.88% | 7.25B | |
+3.57% | 5.86B | |
+11.77% | 5.35B | |
+29.65% | 4.63B | |
-17.74% | 4.19B | |
-35.26% | 2.44B | |
+3.09% | 2.07B |
- Stock Market
- Equities
- BCART Stock
- News Biocartis Group NV
- Biocartis Group NV Reconfirms Earnings Guidance of 2022